Whitney & Co’s Charles River Laboratories CRL Stock Holding History

Whitney & Co’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-150	Closed	-$20K	–	181
2018 Q3	$20K	Buy	+150	New	+$18.5K	﹤0.01%	246

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Whitney & Co's CRL Position: Q4 2018 in Review

Whitney & Co sold out of Charles River Laboratories (CRL) in Q4 2018, closing a stake of 150 shares — an estimated $20K sold.

Whitney & Co first reported a position in CRL in Q3 2018 and held it in 1 quarter. The position peaked at $20K in Q3 2018. 407 funds tracked by Wall St. Rank hold CRL as of Q4 2018.

Whitney & Co reported no remaining Charles River Laboratories position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 150 Charles River Laboratories shares in Q4 2018, an estimated $20K.
Whitney & Co first reported a position in Charles River Laboratories in Q3 2018 and held it in 1 quarter.
Whitney & Co's Charles River Laboratories position peaked at $20K in Q3 2018.
407 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.